Veradermics Reports Positive Phase 2 VDPHL01 Results in FPHL
NEW HAVEN, Conn., July 15, 2026 Veradermics announced positive topline results from its open-label Phase 2 Study 207 evaluating...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
NEW HAVEN, Conn., July 15, 2026 Veradermics announced positive topline results from its open-label Phase 2 Study 207 evaluating...
